The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.

With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.

Although Elonzris, the therapy at the heart of its recent acquisition of Stemline has just been rejected in Europe, Italy's Menarini is pushing on with its expansion in oncology and is paying $30m upfront to get the rights to Radius Health's Phase III hope elacestrant.

The $1.4bn deal will combine Invitae’s centralized laboratory capabilities with ArcherDX’s precision oncology technologies.